Updatemeta-analysis from biomedical literature about MTHFR’polymorphisms and the CML’ risk

##plugins.themes.academic_pro.article.sidebar##

Published Apr 10, 2022
Download
pdf
Vol. 100 No. 4 (2022): Issue Apr 2022

##plugins.themes.academic_pro.article.main##

Fatma Turki
Nour Louati
Hassen Kamoun
Leila Keskes
Tarek Rebaii
Rim Frikha

Abstract

Background : The MTHFR gene polymorphisms are closely related to the chronic myeloid leukemia (CML). Case-control studies have
associated the MTHFR polymorphisms and susceptibility to CML but the results were not conclusive.

Aim : To assess this association through an update meta-analysis.

Methods : A descriptive and qualitative study was conducted among students in the 6th year of the faculty during the academic year 2020/2021.
The data were collected through a questionnaire written in french evaluating the teaching methods. A focus group of ten persons was led to
understand better student’s opinions.

Results : Totally, 17 and 12 case-control studies including CML cases and controls were enrolled in the meta-analysis respectively for C677T and
A1298C polymorphism and CML risk. A poor association between the C677T (T vs C ; OR= 1,28; IC95%= [1,01;1,63]; p=0,04) and the one not
significant between the A1298C (C vs A ; OR= 1,52; IC95%= [0,92; 2,51]; p= 0,1) polymorphisms and the CML risk for overall population were found.

Conclusion : The results of this meta-analysis suggested no significant association between C677T and A1298C polymorphisms and CML
risk leading to consider other factors such us folic acid intake, gene-gene and gene- environment interactions.





##plugins.themes.academic_pro.article.details##

References

  1. Schnakenberg E, Mehles A, Cario G, Rehe K, Seidemann K, Schlegelberger B, et al. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet. 2005 May 27;6(1):23.
  2. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia. 2003 Dec;17(12):2318–57.
  3. Quintás-Cardama A, Cortes JE. Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 2006 Jul 1;81(7):973–88.
  4. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442–59.
  5. Frazer R, Irvine A, Mcmullin M. Chronic Myeloid Leukaemia in The 21st Century. Ulster Med J. 2007 Feb 1;76:8–17.
  6. Chen BA, Jiang N, Ji MJ, Hou P, Lu ZH, Gao C, et al. A new method for 5, 10-methylenetetrahydrofolate reductase single nucleotide polymorphisms genotyping used to study susceptibility of hematological malignancy. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec 1;14(6):1069–73.
  7. Barbosa C, Souza C, Moura Neto J, Arruda M, Barreto JH, Reis M, et al. Methylenetetrahydrofolate reductase polymorphisms in myeloid leukemia patients from Northeastern Brazil. Genet Mol Biol - GENET MOL BIOL. 2008 Mar 1;31.
  8. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol. 1999 Apr;6(4):359–65.
  9. Wiemels J, Smith R, Taylor G, Eden T, Alexander F, Greaves M. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A. 2001 Apr 1;98:4004–9.
  10. Miranda Vilela, Ana Luisa. Role of Methylenetetrahydrofolate Reductase (Mthfr), Glutathione S-transferases (Gsts M1 and T1) and Haptoglobin (Hp) Gene Polymorphisms in Susceptibility to Chronic Myeloid Leukemia (Cml). J Hematol Thromboembolic Dis. 2013 Jan 1;01.
  11. van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects. Am J Hum Genet. 1998 May 1;62(5):1044–51.
  12. Rim Frikha. Assessment of the relationship between methylenetetrahydrofolate reductase polymorphism and acute lymphoblastic leukemia: Evidence from an updated meta-analysis. J Oncol Pharm Practice 0(0) 1–13. cited 2022 Apr 22 . Available from: https://journals.sagepub.com/ doi/abs/10.1177/1078155219900914
  13. Khorshied M, Shaheen I, Khalil R. Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in chronic myeloid leukemia: an Egyptian study. Med Oncol. 2013 Nov 25;31.
  14. Aly RM, Taalab MM, Ghazy HF. MTHFR A1298C and C677T gene polymorphisms and susceptibility to chronic myeloid leukemia in Egypt. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2571–8.
  15. Li B, Zhang J, Wang L, Li Y, Jin J, Ai L, et al. MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies. Tumor Biol. 2014 May 1;35(5):4233–45.
  16. He,H., He, G., Wang, T.,Cai, J., Wang, Y. Methylenetetrahydrofolate reductase gene polymorphisms contribute to acute myeloid leukemia and chronic myeloid leukemia susceptibilities: Evidence from meta-analyses - ProQuest. Cancer Epidemiology 38(5): 471-478. cited 2022 Apr 21 . Available from: https://www.proquest.com/openview/0d6f2a1d1b5495e2c831349c84cb5e83/1?pqorigsite=gscholar&cbl=1226362
  17. Li C, Yichao J, Jiaxin L, Yueting Z, Qin L, Tonghua Y. Methylenetetrahydrofolate reductase gene polymorphism and risk of chronic myelogenous leukemia: a meta-analysis. J BUON Off J Balk Union Oncol. 2015 Dec;20(6):1534–45.
  18. Martorell-Marugan J, Toro-Domínguez D, Alarcón-Riquelme M, Carmona-Saez P. MetaGenyo: A web tool for metaanalysis of genetic association studies. BMC Bioinformatics. 2017 Dec 16;18:563.
  19. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, GarciaOrad A. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2013 Dec;13(6):498–506.
  20. Gurion R, Gafter-Gvili A, Vidal L, Leader A, Ram R, ShachamAbulafia A. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica. 2013 Jan 1;98(1):95–102.
  21. Matthias Egger, George Davey Smith, Martin Schneider, Christoph Minder. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629. cited 2022 Apr 22 . Available from: https://www.bmj.com/content/315/7109/629
  22. Hur M, Park JY, Cho HC, Lee KM, Shin HY, Cho HI. Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol. 2006;28(3):154–9.
  23. Vahid P, Farnaz R, Zaker F, Farzaneh A, Parisa R. Methylenetetrahydrofolate Reductase Gene Polymorphisms and Risk of Myeloid Leukemia: Table 1. Lab Med. 2010 Aug;41(8):490–4.
  24. Lordelo GS, Miranda-Vilela AL, Akimoto AK, Alves PCZ, Hiragi CO, Nonino A. Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res GMR. 2012 Apr 19;11(2):1013–26.
  25. Deligezer U, Akisik E, and D. N., Genotyping of the MTHFR gene polymorphism, C677T in patients with leukemia by melting curve analysis. Mol Diagn, 2003. 7(3–4): 181–5.
  26. 26. Moon, H.W., Kim, T.Y., Oh, B.R. and al., MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res, 2007. 31(9): 1213-7.
  27. Kim, H.N., Kim, Y.K., Lee I.K. and al., Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res, 2009. 33(1): 82-7.
  28. Said I. Ismail, Nida A. Ababneh, and A. Awidi. Methylenetetrahydrofolate Reductase (MTHFR) Genotype Association with the Risk of Chronic Myelogenous Leukemia. Med J 2009. 43(1): 8-14.
  29. Jankovic R.N., Jankovic K., Cavic M., and Malisic E,. Relation of methylenetetrahydrofolate reductase C677T polymorphism to chronic myeloid leukemia in Serbia. J Clin Oncol, 2011. 29(6581).
  30. Hussain, S.R., Naqvi, H., Raza, S.T. and al. Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population. Cancer Epidemiol, 2012. 36(4): e227-31.
  31. Jankovic K, Malisic E, Cavic M, Radulovic S and Jankovic A. Association between methylenetetrahydrofolate reductase polymorphism C677T and risk of chronic myeloid leukemia in Serbian population. Leuk Lymphoma, 2012. 53(7): 1327-30.
  32. Dorgham, S., Aberkane, M,. and Boughrara, W,. Association between methylene-tetrahydrofolate reductase gene polymorphisms and chronic myeloid leukemia . Bull Cancer, 2014. 101(9): 803-7.
  33. Banescu, C., Lancu, M,. Trifa, A.P., and Mascarie, I. The methylenetetrahydrofolate reductase (MTHFR) 677 C>T polymorphism increases the risk of developing chronic myeloid leukemia-a case-control study. Tumour Biol, 2015. 36(4): 3101-7.